Pharmacogenomics: from bedside to clinical practice

被引：49

作者：

Marsh, S ^{[1
]}

McLeod, HL ^{[1
]}

机构：

[1] Washington Univ, Sch Med, Div Oncol, St Louis, MO 63110 USA

来源：

HUMAN MOLECULAR GENETICS | 2006年 / 15卷

关键词：

D O I：

10.1093/hmg/ddl087

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The field of pharmacogenomics has seen some exciting advances in the recent past. The Human Genome Project and International HapMap projects have uncovered a wealth of information for researchers. The discovery of clinically predictive genotypes (e.g. UGT1A1*28, TYMS TSER), haplotypes (e.g. VKORC1 Haplotype A) and somatic mutations (e.g. epidermal growth factor receptor), along with the introduction of FDA approved pharmacogenetic tests (UGT1A1*28) and the initiation of a genotype-guided clinical trial for cancer therapy (TYMS TSER in rectal cancer) have provided the first steps towards the integration of pharmacogenomics into clinical practice. This review describes some of the recent advances in pharmacogenomics research.

引用

页码：R89 / R93

页数：5

共 46 条

[21]

Kawakami K, 1999, ANTICANCER RES, V19, P3249

[22] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].

Kobayashi, S ;

Boggon, TJ ;

Dayaram, T ;

Janne, PA ;

Kocher, O ;

Meyerson, M ;

Johnson, BE ;

Eck, MJ ;

Tenen, DG ;

Halmos, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792

[23] Incidence of adverse drug reactions in hospitalized patients - A meta-analysis of prospective studies [J].

Lazarou, J ;

Pomeranz, BH ;

Corey, PN .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (15) :1200-1205

[24] Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin [J].

Leichman, CG ;

Lenz, HJ ;

Leichman, L ;

Danenberg, K ;

Baranda, J ;

Groshen, S ;

Boswell, W ;

Metzger, R ;

Tan, M ;

Danenberg, PV .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (10) :3223-3229

[25] Identification of the gene for vitamin K epoxide reductase [J].

Li, T ;

Chang, CY ;

Jin, DY ;

Lin, PJ ;

Khvorova, A ;

Stafford, DW .

NATURE, 2004, 427 (6974) :541-544

[26] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[27]

Mandola MV, 2003, CANCER RES, V63, P2898

[28]

Margaglione M, 2000, THROMB HAEMOSTASIS, V84, P775

[29]

MARKETOS M, 2004, DRUG TOPICS, V148, P82

[30] Cancer pharmacogenetics [J].

Marsh, S ;

McLeod, HL .

BRITISH JOURNAL OF CANCER, 2004, 90 (01) :8-11

← 1 2 3 4 5 →